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1. ABSTRACT 
 
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in the regulation of the cross talk between 
haematopoietic/immune cells and stromal cells, including the onset and resolution of inflammation, responses to infection, tissue 
remodelling and cancer. It is produced, among others, by fibroblasts, endothelial cells, macrophages and lymphocytes. IL-6 can 
interact with both membrane-bound and soluble forms of its ligand-binding receptor, the IL-6Ralpha, triggering signalling via 
dimerization of gp130, the signalling subunit of the IL-6 receptor complex. This leads to the activation of the JAK/STAT 
pathway and mainly culminates in the activation of the STAT3 transcription factor. Both IL-6 and STAT3 have recently emerged 
as main regulators of the differentiation and function of Th17 cells, via a positive feedback loop enhancing expression and/or 
activation of IL-6 itself, IL-17 and STAT3. Dysregulated IL-6 production and signalling are associated with chronic 
inflammatory diseases, auto-immunity and cancer, and are the object of intense translational research as promising therapeutic 
targets.  
 
2. INTRODUCTION 
 
IL-6  was  initially  identified  in  the  ‘80s  as  a  factor  inducing  the  terminal  maturation  of  B-lymphocytes into antibody-
producing plasma cells. It was then implicated in T lymphocytes survival and in stimulating proliferation and/or differentiation of 
various haematopoietic stem cell lineages (reviewed in (1)). Additionally, it was identified as an essential mediator of host 
responses to acute inflammation, including the acute phase response in the liver (2, 3). Most cell types, including T and B-
lymphocytes, phagocytic cells, fibroblasts, endothelial and epithelial cells, can produce IL-6 in response to a wide range of 
stimuli such as bacterial or viral infection, inflammation and inflammatory cytokines. Once produced, IL-6 participates in tissue 
defences and healing, regulating local influx and maturation of leukocytes and promoting tissue remodelling. IL-6 secretion is 
normally tightly controlled, and indeed its excessive and continuous production has been implicated in the pathogenesis of post-
menopausal osteoporosis, auto-immune disorders, plasma-cell dyscrasias and many types of cancer (4). 
 
IL-6 signalling (Figure 1) occurs through the assembly of a receptor complex composed of two subunits, the ligand 
binding IL-6Ralpha and the signal transducing gp130 (reviewed in (5)). Gp130 also acts as a signalling subunit for a family of 
cytokines structurally related to IL-6: Leukaemia Inhibitory Factor (LIF), Oncostatin M (OSM), Ciliary Neurotrophic Factor 
(CNTF), Interleukin-11 (IL-11), Interleukin-27 (IL-27), cardiotrophin-1, cardiotrophin-related cytokine (CLC), and neuropoietin 
(NPN) (reviewed in (6) and in (7)). In contrast with IL-6 and IL-11, which trigger the homodimerization of gp130, most of the 
other family members assemble a heterodimeric complex between gp130 and a second signalling molecule, the LIFRbeta, the 
OSMRbeta or the IL-27Ralpha (7). The common sharing of gp130 and the differential involvement of the LIFRbeta and 
OSMRbeta are likely explanations for the overlapping and diverging functions displayed by these cytokines. The IL-6Ralpha 
cytoplasmic domain is not required for signalling, and soluble IL-6Ralpha forms (sIL-6Ralpha) can act as agonists, conferring 
IL-6 responsiveness to cells that only harbour gp130 (reviewed in (8)), a phenomenon known as IL-6 trans-signalling. Circulating 
sIL-6Ralpha, generated by alternative splicing or, more frequently, by ADAM17-mediated shedding from the cell surface (9), is 
naturally present in body fluids of both humans and mice, and its production is specifically increased in a variety of pathological 
conditions such as infection, inflammation and tumour progression (10-16). Indeed, sIL-6R is abundantly produced in patients 
with chronic inflammatory disorders, where it contributes to disease progression. IL-6 trans-signalling plays an important role in 
controlling leukocyte infiltration at sites of acute and chronic inflammation/infection (12). Neutrophils, the first cells infiltrating 
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inflamed areas, undergo caspase-dependent activation of the ADAM17 protease, which in turn promotes shedding and local 
release of the sIL-6R. In the presence of inflammation-driven IL-6 production, this allows IL-6 trans-signalling to act on stromal 
cells that lack the membrane-bound IL-6R, up-regulating the expression of adhesion molecules and chemokines such as ICAM-1, 
VCAM-1, CXCL1, CXCL5, CXCL6, CXCL8, CCL2 (17). These in turn promote recruitment of macrophages, involved in 
neutrophil clearance and antigen presentation, and lymphocytes (18). These events are essential for the resolution of the 
inflammatory reaction and for initiating acquired immunity. Accordingly, increased and prolonged neutrophil accumulation at 
sites of inflammation is observed in IL-6 deficient mice (19). The importance of maintaining IL-6 signaling/trans-signaling under 
tight regulation is highlighted by the observation that under inflammatory conditions also gp130 can be produced in a soluble 
form that acts as a specific antagonist of IL-6 trans-signalling (20). 
 
The interaction of IL-6 with its receptor complex triggers the activation of associated JAK kinases, leading to the 
phosphorylation of five tyrosine residues on the cytoplasmic portion of gp130 (21). The phosphotyrosine residues in turn allow 
recruitment and activation of members of the Signal Transducer and Activator of Transcription family of transcription factors on 
one hand, and on the other hand of the SHP2 adaptor, leading to the activation of the Ras-MAP kinase pathway that mainly 
culminates in the induction of members of the C/EBP family of transcription factors (22). Finally, SOCS3, a STAT3 immediate 
early target gene, is recruited to the same phosphotyrosine residue as SHP2, mediating a negative feedback via inactivation of 
JAKs (23). STAT factors mediate the signalling downstream of cytokine and growth factor receptors. They become activated by 
JAK-mediated tyrosine-phosphorylation, upon which they form anti-parallel dimers that concentrate into the nucleus regulating 
the expression of target genes (24). All members of the IL-6 cytokine family were shown to be able to activate STAT3 and, to a 
lesser extent, STAT1. 
 
STAT3 is recognized as the main mediator of IL-6 functions. Its activation occurs not only downstream of all members 
of the IL-6 family of cytokines, but also of a great number of other cytokines, growth factors and oncogenes including leptin, IL-
12, Interferons, IL-10, G-CSF and Src (25). STAT3 itself is considered an oncogene, since it is constitutively tyrosine-
phosphorylated in a high percentage of tumours and tumour-derived cell lines of both liquid and solid origin, where its inhibition 
often triggers growth arrest and/or cell death (26-29).  
 
 STAT3 was initially identified as Acute Phase Response Factor (APRF), a DNA-binding activity appearing in IL-6-
treated hepatocytes and interacting with an Acute Phase Response Element (APRE) on the promoter of several IL-6-responsive 
genes (30). Molecular cloning identified then STAT3/APRF as the EGF-dependent factor binding to a sis-inducible element on 
the c-fos promoter (31-33). STAT3 can form both homo- and hetero-dimers with STAT1 and binds to sequences very similar to 
the GAS sites, the typical STAT1 recognition elements (34).  
 
 Both in vitro and in vivo studies have shown that one of the peculiar characteristics of STAT3 is its capacity to activate 
different sets of genes in different cell types. This is probably achieved through specific interactions with distinct transcription 
factors/co-factors in different cell and promoter contexts (e.g. AP1, NF-kB, CBP/p300, NCoA-1/SRC-1, NCoR2, PCAF, GCN5, 
mSin3, HDACs) (35-39). In addition, STAT3 exists in two alternatively spliced forms, the full length STAT3alpha and the 
truncated STAT3beta, which lacks the carboxy-terminal activation domain and was initially considered as a dominant negative 
form (40, 41), but was recently shown to exert both negative and positive effects on transcription (42). The final outcome of 
STAT3 activation in a specific cellular compartment will thus likely depend on the physiological/pathological context, which in 
turn will determine a specific cytokine/growth factor milieu and therefore coordinated activation of different factors including 
STAT3 (alpha and/or beta).  
 
 In this review, we summarize the current knowledge about the role of IL-6 in several auto-immune diseases, and 
correlate it to a pathogenetic mechanism involving the transcription factor STAT3 and the action of T helper 17 cells. The 
relevance of this IL-6-IL-17-STAT3 loop is then examined in inflammation-related tumourigenesis, where the IL-6/STAT3 axis 
is already known to play a crucial role. 
 
2.1. IL-6 in the development of auto-immunity 
Failure of the immunological safeguard mechanisms leading to discriminate self from non-self results in auto-immune 
diseases, which can affect many organs and tissues including thyroid, pancreas, adrenal glands, red blood cells and connective 
tissues (skin, muscle and joints).  Auto-immune diseases can be either organ-specific, such as the pancreas in insulin-dependent 
diabetes, the thyroid in Hashimoto's thyroiditis and Graves' disease and the heart in myocarditis, or non-organ-specific, such as 
rheumatoid arthritis, multiple sclerosis, lupus erythematosus and myasthenia gravis (43). Auto-immune diseases can have many 
different causes and the exact aetiology of acquired auto-immunity is still not clear. A leading hypothesis to explain the onset of 
several different auto-immune diseases is that the immune response mounted against infectious agents can lead to break the 
tolerance versus self-antigens sharing common antigenic features (44). Auto-immune reactions share several common features 
like development of auto-antibodies, T cell proliferation and activation, tissue damage and increased production of pro-
inflammatory cytokines like TNFalpha, IL-1, IL-2, IL-17, IL-6 and IFNgamma (45-48). There are abundant clinical data 
suggesting that IL-6 plays critical roles in the pathogenesis of auto-immune diseases, which have been dissected through the 
analysis of several animal models. 
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2.1.1. IL-6 and rheumatoid arthritis 
Rheumatoid arthritis (RA) is a common human auto-immune disease that affects joints and occasionally other tissues 
(reviewed in (49)). It is characterized by chronic inflammation of the synovial joints, excess synovial fluid production and 
development of a synovial pannus. The pannus is a membrane of granulation tissue covering the normal surface of the articular 
cartilages, which leads to destruction of the articular cartilage and bone erosion (50). Activation of immune cells is observed, as 
well as high local production of pro-inflammatory cytokines such as TNFalpha, IL-1 and IL-6, which are thought to play a central 
pathogenic role (51, 52). Both serum and synovial fluids of patients with active RA or juvenile rheumatoid arthritis display very 
high levels of IL-6 (53, 54), believed to act both locally and systemically (52, 55). Moreover, also synovial sIL-6R levels increase 
with disease progression (56). In addition to stimulating B and T cell functions, in conjunction with sIL-6R IL-6 can activate 
the production of a subset of chemokines and adhesion molecules by endothelial cells (19), which lack membrane-bound IL-6R, 
and induce osteoclasts formation and activation (56, 57). Several studies have suggested that synovial fibroblasts (SFs) may have 
a critical pathogenic role via the production of proinflammatory cytokines and of proteases, such as matrix metalloproteinases, 
responsible for tissue destruction (58). Data on the role of IL-6 in SFs are contrasting. SFs are devoid of IL-6R and soluble IL-6R 
must therefore be present in order to elicit an IL-6 response (59). Mihara et al. reported IL-6 trans-mediated-mediated stimulation 
of SF proliferation (60). In contrast, Nishimoto and co-authors reported that IL-6 plus sIL-6Ralpha inhibits TNFalpha-induced SF 
proliferation. Since TNFalpha induces IL-6 production, IL-6 would in this case be part of a negative feedback loop (61). 
Although the exact IL-6-mediated pathogenic mechanism in RA is still incompletely understood, remarkably a humanized anti-
IL-6R monoclonal antibody (62) has been recently approved for the treatment of moderate to severe RA in adult patients not 
responding to previous therapy with one or more disease-modifying anti-rheumatic drug(s) (63).  
 
Several models of arthritis have been established in the mouse and rat. The one that perhaps resembles RA more closely 
is collagen-induced arthritis (CIA), which elicits an auto-immune response against cartilage components (64). CIA is induced by 
immunization with autologous or heterologous type II collagen in susceptible DBA/1J mice, leading to break tolerance against 
murine collagen thus initiating the disease. CIA resembles RA in a number of features including chronic proliferative synovitis 
with infiltration of polymorphonuclear and mononuclear cells, pannus formation, cartilage degradation, bone erosion and fibrosis. 
Antigen induced arthritis (AIA) (65) is a mono-articular chronic form of immunological arthritis triggered by intra-articular 
injection of methylated bovine serum albumin (mBSA) in susceptible strains of mice (C57BL/6 and BALB/c) previously 
sensitized by immunization with the same antigen. Also AIA reproduces many features of RA such as synovial lining 
hyperplasia, proliferation of sublining cells, infiltration of inflammatory cells, revascularization, pannus formation and articular 
cartilage destruction. Both CIA and AIA are considered T-cell dependent arthritides. Finally, zymosan-induced arthritis (ZIA) 
(66) is a purely inflammatory model of proliferative arthritis, triggered by direct injection of the inflammatory compound 
zymosan A into the knee joint cavity and not dependent on the adaptive immune response. Indeed, zymosan A, which is a ligand 
for toll-like receptor 2 as well as an activator of the alternative complement pathway, triggers local activation of the innate 
immune system causing inflammation in the injected joint.  
 
Making use of IL-6 deficient mice several groups have demonstrated a pathogenic role of IL-6 in experimentally 
induced auto-immune arthritis. IL-6 deficiency results in partial to complete resistance to CIA, as judged by tissue damage, with 
reduction of both humoral and cellular responses to type II collagen and a shift toward a Th2-type immune response (67, 68). 
Comparable results have been obtained in AIA, where lack of IL-6 resulted in strongly reduced disease incidence and score and 
in protection from cartilage destruction and osteoclasts activation (69, 70), correlating with lower auto-antibody titers and 
reduced specific proliferative T cell responses. There are indications that both systemic and local IL-6 production are involved in 
disease pathogenesis. Indeed, recombinant IL-6 injected either sub-cutaneously or locally in the knee joint could completely or 
partially restore sensitivity to AIA (70). Moreover, IL-6 production by bone marrow–derived haematopoietic cells must play an 
important role, since bone marrow transfer from a sensitised donor can transfer AIA to wild type mice depleted from B and T 
cells only if derived from an IL-6-sufficient mouse (71). In the ZIA model, the absence of IL-6 results in acute inflammation 
(characterized by neutrophil influx) and increased cartilage destruction. However, wild type mice develop more severe joint 
inflammation, with enhanced infiltration of monocytes and osteophyte formation during the chronic phase (72-74), suggesting a 
major role for IL-6 in the transition from the acute to the chronic phase in ZIA (reviewed in (75)). Local IL-6 production may act 
via IL-6 trans-signalling, since its specific blockade via sgp130 alleviates disease symptoms, while intra-articular administration 
of hyper IL-6, a recombinant protein generated by the fusion between IL-6 and sIL-6Ralpha, can restore arthritis in IL-6-/- mice 
(13). 
 
In conclusion, there is a general agreement that IL-6 plays a pathogenic role in all three models of arthritis examined, 
with particularly clear-cut results obtained in the two models of immunological arthritides that more closely resemble RA. 
Although the exact mechanism through which IL-6 exerts its pathogenic role is still not completely elucidated, it is likely to 
occur at multiple levels including i) promotion and maintenance of the chronic inflammatory response both systemically and 
locally, which in turn contributes to stimulating and amplifying T-cell dependent B cell responses to arthritogenic antigens; ii) 
induction of osteoclastogenesis and osteoclasts activity and iii) enhancing the production of molecules contributing to tissue 
destruction such as prostaglandins and nitric oxide by monocytes and synovial fibroblasts. On the other hand, TNFalpha and IL-
1beta are both amply recognised as important players in the pathogenesis of RA and of other forms of arthritis, and both are 
potent inducers of IL-6 synthesis. It is thus not surprising that IL-6 may mediate at least some of their arthritogenic effects. 
Interestingly, the inflammatory polyarthritis caused by expression of an abnormally stable form of human TNFalpha in transgenic 
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mice develops normally in IL-6-/- mice (67), suggesting that the need for IL-6 can be bypassed when the production of key 
inflammatory cytokines is outwith physiological means of control.  
 
2.1.2. IL-6 and multiple sclerosis 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system characterized by inflammation, 
demyelination and axon degeneration and leading to muscle weakness and ataxia. Its aetiology remains unknown and disease 
processes are still poorly understood. The observation that immunosuppressive treatment with cyclophosphamide (76), cladribine 
(77) or mitoxantrone (78) can limit disease activity suggested that MS is an immunologically mediated disease.  
 
 Several studies identify IL-6 as an important player in the onset and exacerbation of MS, since its levels are increased 
in the serum and cerebrospinal fluid of MS patients (79-81), in MS lesions (82, 83) and in mononuclear cells from cerebrospinal 
fluid and blood of MS patients (84). Auto-immune reactivity against minor components of myelin are thought to play an 
important role in the pathogenesis of multiple sclerosis. In particular, MS patients exhibit a predominant T cell response to 
myelin oligodendrocyte glycoprotein (MOG), which is rarely observed in the serum of healthy controls (85, 86).  
 
 Synthetic MOG peptides (pMOG) or myelin basic protein (MBP) are encephalitogenic in H-2b strains of mice such as 
C57BL/6 and 129, where they can induce experimental auto-immune encephalomyelitis (EAE), the best experimental model of 
MS so far. EAE is characterized by an ascending paralysis correlating with inflammation and tissue damage (87). Pathological 
features of EAE are perivascular inflammatory infiltrates of lymphocytes, macrophages and microglia in the brain and spinal 
cord, correlating with areas of demyelination. Affected animals show high levels of IL-6 in the central nervous system, high 
autoantibody levels against myosin and tissue infiltration of myelin-specific Th1 cells.  
 
Remarkably, IL-6-deficient mice were completely resistant to EAE, showing neither clinical symptoms nor 
inflammatory infiltrate in the brain and spinal cord (88-92). A shift toward a Th2-type anti-inflammatory response was observed, 
with production of IL-10 and IL-4 (89-92). Lack of inflammatory infiltrate correlated with decreased VCAM-1 and ICAM-1 
expression by endothelial cells in the central nervous system. IL-6-dependent up-regulation of these adhesion molecules is 
thought to cause breakdown of the blood brain barrier and T cell entry (89, 91, 93). 
 
Although serum titers of anti-MOG auto-antibodies were decreased in the IL-6-/- mice, this could not per se warrant 
protection as B-lymphocytes are not required for EAE pathogenesis (89). Accordingly, the partial rescue of disease development 
observed upon injection of recombinant IL-6 did not correlate with increased antibody production (88). T cell priming, impaired 
in pure C57BL/6 IL-6 deficient mice, was in contrast normal in the (C57BL/6x129) F1 genetic background even though these 
were still protected from disease development (88, 90, 92). Protection cannot therefore be ascribed to impaired T cell reactivity 
either. Accordingly, T cell lines exhibiting high proliferative responses to MOG could be derived from both mutant and wild type 
mice (88). Interestingly, IL-6-/- T lymphocytes were unable to confer EAE to an IL-6+/+ recipient (88), while IL-6+/+ T cells could 
successfully transfer EAE, but to a wild type recipient mouse only, suggesting that the pathogenic role of IL-6 in EAE rests on 
both T cell-dependent and independent functions. Accordingly, transgenic mice producing IL-6 specifically in the cerebellum 
show EAE development in this region rather than in the spinal cord, suggesting that localized secretion of IL-6 is enough to 
redirect the disease (94). Which other players are involved in addition to T cells? IL-6 appears to be important to establish the 
local perivascular inflammatory process characteristic of the disease, as already suggested by the failure of IL-6+/+ T cells to elicit 
inflammation when transferred into IL-6-/- recipients (88). Moreover, disease in the IL-6-/- mice can be partially rescued by 
injection with IL-8, a chemo-attractant whose secretion by endothelial cells is induced by IL-6 in combination with sIL-6R (88). 
Finally, injection of superantigen (staphylococcal enterotoxin B) increased VCAM-1 expression in brain endothelium and 
partially reversed resistance of IL-6-/- mice to EAE (95). In conclusion, IL-6 plays a fundamental role in the pathogenesis of auto-
immune encephalomyelitis, both by stimulating an encephalitogenic T cell response and by establishing the local inflammatory 
response via the induction of chemokines and the activation of the endothelium, possibly also increasing the permeability of the 
blood-brain barrier (96). These observations highlight the relevance of feedback interactions between stromal cells and T cells in 
the development of MS and likely other auto-immune diseases, and suggest that IL-6 production by both compartments plays a 
crucial role in this cross-talk. 
 
2.1.3. IL-6 and myocarditis 
Acute myocarditis can initiate a chronic immune-mediated inflammation of the heart, possibly leading to dilated 
cardiomyopathy (DCM) with chronic heart failure. In many developing countries, myocarditis remains a significant cause of 
morbidity and mortality in the young adult. The main recognized cause is a viral infection of the heart, particularly with strains of 
the coxsackievirus. Possible mechanisms include direct viral destruction of cardiac myocytes, which can lead to T-cell-mediated 
auto-immune injury, and viral-mediated endothelial injury that triggers an inflammatory response leading to tissue damage 
including necrosis. Bacterial pathogens, hypersensitivity reactions, cancer or pre-existing systemic diseases such as the Churg-
Strauss syndrome, are also implicated as co-factors (97-99). Elevated levels of Fas and Fas ligand as well as elevated IL-10 
serum levels are predictors of poor prognosis in patients with fulminant myocarditis (100, 101). 
 
Experimental auto-immune myocarditis (EAM) is an auto-immune disorder that resembles CD4+-mediated human heart 
inflammation. It can be induced in susceptible mice (BALB/c, CBA/J and A/J) by infection with coxsackievirus B3 (CVB3) 
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(102) or by immunization with cardiac myosin or derived peptides (103). Cytokines like TNFalpha (104), IL-4 (105) and IL-12 
(106, 107) are essential for the development of the disease, whereas IFNgamma is protective (108). Several studies have 
demonstrated that also IL-6 plays an important role in EAM. Indeed, IL-6 deficient mice developed a milder disease, with low 
prevalence and reduced severity (109). Decreased VCAM-1 and ICAM-1 expression on endothelial cells and lower levels of 
complement C3 and TNFalpha are responsible for the less efficient recruitment of auto-reactive T cells to the heart of IL-6-
deficient mice. Of note, the proliferation of IL-6-deficient auto-reactive CD4+ T cells is impaired. Similar to what observed also 
in RA and MS models, specific auto-antibody levels are lower in the IL-6-/- mice as compared to wild type mice, but this is not 
responsible for the altered course of myocarditis.  
 
The pathogenic role of IL-6 in auto-immunity is probably not limited to the above described pathologies, as abundant 
IL-6 production and beneficial effects of IL-6 neutralization have been observed in other auto-immune diseases such as uveitis or 
systemic lupus erythematosus (62). 
 
3. THE DISCOVERY OF TH17 CELLS SHED LIGHT ON THE ROLE OF IL-6 IN AUTO-IMMUNE DISEASES 
  
The above reported findings all point towards an important role of IL-6 in mediating CD4+ T cell responses and chronic 
local and systemic inflammation, leading to the development of auto-immunity. This was to a certain extent puzzling, since until 
a few years ago inflammation and auto-immune diseases were thought to be caused by the activation of CD4+ T helper 1 (Th1) 
cells, not functionally linked to IL-6 production.  
 
Th1/Th2 cell polarization is a central paradigm in T-cell mediated immunity. These cells differentiate from naive 
populations of CD4+ lymphocytes exposed to specific stimuli and cytokine milieu, and in turn are characterized by distinct 
repertoires of cytokine production (reviewed in (110)). Th2 responses, characterized by IL-4, IL-5, IL-9 and IL-13 secretion, are 
classically linked to antibody-mediated responses and allergy, whereas Th1 cells, characterized by secretion of IFNgamma, IL-2 
and TNFalpha, were generally associated with T cell-mediated responses to intracellular pathogens and auto-immune diseases. 
The finding that mice lacking IFNgamma, the main Th1-driving cytokine, still developed inflammatory and auto-immune 
diseases (106, 107, 111-115), suggested however the involvement of other players. Additionally, IL-12Rb2-/- and IL-12p35-/- 
mice (116-118), which lack critical components of the Th1-IFNgamma pathway, were highly susceptible to inflammatory auto-
immune diseases. These findings questioned the role of Th1 CD4+ T cells in auto-immune pathogenesis and set the stage for the 
search of other players. A novel effector lineage of T helper cells, the so-called Th17 cells, characterized by the production of IL-
17 and involved both in providing defence against extracellular bacteria and in mediating inflammation, was indeed recently 
identified (119, 120). IL-17 belongs to the small IL-17A-F family of cytokines, which is generally thought to enhance 
inflammation by stimulating the recruitment of other immune cells to peripheral tissues (121-123). Recent studies report that 
excessive IL-17 production exerts harmful effects in auto-immune and chronic inflammatory disorders in both the human and the 
mouse, because of its ability to trigger tissue damage. The important role of Th17 cells in human immune-mediated/inflammatory 
diseases has been suggested by the isolation of IL-17-producing cells in patients with contact dermatitis (124, 125) and in both 
brain lesions and mononuclear cells isolated from blood and cerebrospinal fluids of multiple sclerosis patients (126-128). 
Moreover, IL-17 is detectable in the synovial fluid from rheumatoid arthritis patients and can enhance osteoclastogenesis by 
inducing the receptor activator of NF-kB ligand (RANKL) on mesenchymal cells (129). Consistently, IL-17 plays a critical role 
in a model of bone loss induced by local inflammation, suggesting that Th17 cells may play a role in the destruction phase of 
auto-immune arthritis (130).  
 
 IL-17 critical role in auto-immune conditions has been extensively demonstrated also in mouse models. IL-17A gene 
inactivation suppressed the development of EAE, CIA and the arthritic disorders that develop in IL-1Ra-/- mice (116, 131-133). 
Mice deficient for RORgammat, a transcription factor required for IL-17 differentiation, show attenuated EAE (134). In addition, 
IL-17-producing cells are critical for EAM pathogenesis, and its depletion reduces disease severity (135, 136). IL-17 is also 
increased in lymphocytes derived from mice with EAE (137) and its neutralization during the elicitation phase suppresses disease 
development (138). The demonstration that adoptive transfer of specific Th17, but not Th1, cells induces EAE (138) has 
unambiguously established a pathogenic role for these cells. SKG mice, which carry a homozygous G-to-T substitution in the 
ZAP-70 gene and spontaneously develop an auto-immune arthritis-like disease when housed under non specific pathogen free 
conditions, show massive infiltration of IL-17 secreting cells in the joints and high local expression of IL-17 mRNA (113, 114). 
Accordingly, the transfer of CD4+/IL-17-/- cells from SKG mice into Rag2-/- mice fails to induce arthritis, confirming the essential 
role of IL-17-producing Th17 cells in this model (114).  
 
The link between the well documented pathogenic role of IL-6 and that of IL-17/Th17 cells in auto-immunity was 
provided by the exciting finding that the differentiation of Th17 cells from naïve T cells, occurring in the periphery, requires the 
action of IL-6 combined, at least in mice, with transforming growth factor beta (TGFbeta) (114, 139). Moreover, in vivo Th17 
differentiation in experimental auto-immune uveoretinitis (EAU) is impaired in the absence of IL-6, leading to disease protection 
(140). Interestingly, in vitro stimulation of naive CD4+ T lymphocytes with TGFbeta alone triggers the generation of regulatory T 
lymphocytes (Treg), another CD4+ T cell subset with the ability to suppress immune responses against self- and non self- 
antigens and involved in the process of auto-immunity, transplant rejection, infectious diseases and cancer. Moreover, IL-6 trans-
signalling can block Treg development through up-regulation of SMAD7, which inhibits TGFbeta signalling thus decreasing 
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tolerance and perpetuating chronic inflammatory diseases (141). It is indeed postulated that the Treg and Th17 lineages are 
somewhat related, with their specific differentiation being mutually exclusive (142, 143). However, the functional segregation of 
the different types of CD4+ Th lymphocytes is likely not as rigid as initially thought. For example, McGeachy and colleagues 
have demonstrated that activated Th17 cells continuously stimulated with TGFbeta and IL-6 can down-regulate the expression of 
genes encoding for several pro-inflammatory chemokines and initiate the production of IL-10 (144), thus switching to an anti-
inflammatory function. This may represent a negative feedback mechanism contributing to control Th17 pro-inflammatory 
responses. Until recently, human Th17 cells were considered different from their murine counterparts, since they express also 
Th1-related proteins such as IL-12R beta2 and T-bet, they produce both IL-17A and IFNgamma and, upon IL-12 stimulation, and 
they are able to shift to a Th1 phenotype (145). Moreover, in addition to IL-6 they require IL-1beta and IL-23 but not TGFbeta 
for their in vitro differentiation. However, also murine Th17 cells have been recently shown to be able to convert into Th1-like 
lymphocytes (146-148), and to rapidly switch to IFNgamma production in EAE (149) and in a model of type I insulin-dependent 
diabetes mellitus (150). Thus, the main difference between the murine and human system appears to be the requirement for 
TGFbeta (151). 
 
Other pro-inflammatory cytokines have the ability to enhance Th17 responses, at least in vivo. For example IL-1b
which is abundantly present in MS lesions (152), plays a central role upstream of IL-17 in promoting EAE since IL-1R-/- mice are 
resistant to the disease due to a specific defect in the Th17 response (153). IL-23, produced by activated antigen presenting cells, 
appears to play a prominent role in sustaining Th17 responses and chronic lesions, since IL-23-deficient mice contain very few 
Th17 cells and are protected from auto-immune diseases such as EAE and CIA (136, 138, 154, 155). In addition, IL-17 was 
shown to promote EAM in an IL-23-dependent way (136). Indeed, neutralization of either IL-17 or IL-23 ameliorates heart 
disease even if priming and proliferation of myosin-specific Th1 CD4+ cells are not affected. IL-22 is also abundantly released by 
Th17 cells in response to IL-23, supporting the idea that IL-23 can modulate Th17 cells effector functions (156). A crucial role 
for IL-22 has been shown in innate skin immunity, where it appears to directly increase the innate response against pathogens in 
keratinocytes (157). Both IL-17 and IL-22 were suggested to also induce endothelial cells of the blood-brain barrier to secrete 
cytokines and chemokines such as MCP-1, IL-6 and CXCL8. These in turn favour disruption of the tight-junctions and increased 
vessels permeabilization, thus promoting transmigration of CD4+ T lymphocytes (126). IL-21 was shown to drive Th17 
differentiation in vitro (158, 159), but its activity is not critical in vivo since IL-21-/- and IL-21R-/- mice develop severe EAE and 
EAM, sustained by IL-6 (159, 160). Recently, GM-CSF was also proposed to play a critical role in the development and survival 
of Th17 cells, since it can stimulate dendritic cells to produce IL-6 and IL-23 (161).  
 
Psoriasis is another chronic inflammatory disease where IL-6, together with T-cell mediated immune responses, is 
known to play a critical role (162-166). Recently, psoriasis patients were shown to display preponderance of the IL-23/Th17 axis 
(167, 168), abnormal Th1 responses with elevated IFNgamma and TNFalpha levels (169), and defective activity of Tregs (168, 
170). It was shown that overproduction of IL-6 by endothelial cells and antigen-presenting cells in the lesions lead to reduced 
Treg activity and subsequent hyper activation and proliferation of infiltrating T lymphocytes, contributing to CD4+ T cells 
chronic expansion and driving Th17 differentiation (168). Indeed, Th17 cells have been recently observed in cell suspensions 
from psoriatic skin (171), and IL-17 neutralization arrests disease progression (170).  
 
These observations collectively support a generalized pathogenic mechanism leading to chronic inflammation and, 
under certain circumstances, to auto-immunity, based on a positive circular feedback loop where continuous local and systemic 
production of IL-6 sustains and is in turn sustained by local differentiation and concentration of Th17 cells. An important role is 
played in this context by IL-6 trans-signalling. Indeed, both IL-6 trans-signalling blockade and IL-6 deficiency are associated 
with reduced infiltration and increased apoptosis of T lymphocytes in several models of chronic inflammation (11, 172-175). For 
example, IL-6 deficiency leads to impaired peritoneal infiltration of IFNgamma- and IL-17-secreting cells and down-regulation 
of IL-6R expression (175). IL-6 trans-signalling may directly affect T cell activation, trafficking and apoptosis (11, 14, 15, 172), 
activities already associated with IL-6 itself (176-178). Interestingly, IL-6R expression is restricted to naïve and central memory, 
not effector, T cell subsets both in human and in the mouse (172, 175). Indeed, activated T cells within the inflammatory 
microenvironment, including Th17, selectively downregulate membrane-bound IL-6R expression via protease-mediated 
shedding, associated with increased sIL-6R levels (175, 179). Thus, local regulation of activated T cell responses to IL-6 
critically rely on sIL-6R and IL-6 trans-signalling, which was shown to promote the maintenance of IL-17-secreting CD4+ T cells 
at the site of inflammation (175). 
 
4. STAT3 ENTERS THE GAME 
 
Being STAT3 the main mediator of IL-6 responses, its involvement in Th17 cells differentiation was predictable. 
Indeed, it was shown that differentiation of Th17 cells in response to IL-6 and TGFbeta did not require either STAT4 or STAT6, 
the leading transcription factors regulating Th1 and Th2 responses, but involved STAT3 activation instead. Th17 cells 
differentiation was abrogated in the absence of STAT3 both in vitro and in vivo (180, 181). Overexpression of a constitutively 
active form of STAT3, STAT3C, resulted in greatly increased numbers of IL-17 producing cells and enhanced expression of 
RORgammat in in vitro differentiated CD4+ lymphocytes (182). Moreover, STAT3 depletion in haematopoietic stem cells or 
specifically in CD4+ lymphocytes resulted in dramatic reduction in the number of Th17 lymphocytes (182, 183). Additionally, 
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the STAT3 negative regulator SOCS3 also counteracts Th17 differentiation, as SOCS3 deficient mice showed enhanced Th17 
cells generation associated with widespread auto-immune disease (184). 
 
 The role of STAT3 in Th17 cells appears to go beyond it simply mediating IL-6-triggered differentiation, since this 
factor is activated also by IL-23, which is required for amplification and maintenance of Th17 responses, and by IL-21, which 
also contributes to Th17 differentiation (184, 185). After the initial finding that STAT3 directly activates transcription from the 
Il-17A and Il-17F gene promoters (186), it was recently shown that STAT3 binds to and regulates multiple other key genes 
involved in Th17 cell differentiation, activation, proliferation and survival such as Rorgammat, Roralpha, Batf, Irf4, Ahr, Il-
6ralpha and c-maf (187). The contribution of STAT3 to Th17 differentiation is balanced by STAT5, as the two factors can bind 
to the same DNA motif in the Il-17 locus. IL-2-activated STAT5 can displace STAT3 from the Il-17 promoter, and recruits the 
transcriptional repressor NCoR2 (37). Accordingly, IL-2 deficiency leads to enhanced in vitro and in vivo IL-17 production, 
suggesting that Th17 differentiation depends on the relative concentrations of IL-2 and IL-6 and on the consequent balance 
between activated STAT3 and STAT5 (188). The role of STAT3 in Th17 differentiation also in humans is highlighted by the 
observation that patients with hyper-immunoglobulin E syndrome (HIES), who show stat3 inactivating mutations (189, 190), 
display impaired Th17 differentiation (191, 192). This may explain the recurrent infections characteristic of the disease. 
 
 Additionally, STAT3 is known to contribute to T cell pathogenicity by regulating T cells expansion and homeostasis 
during inflammation. Indeed, STAT3 was shown to activate anti-apoptotic and pro-proliferative genes such as Bcl2, Jun and Fos, 
and to inhibit Tregs conversion downstream of IL-6 and IL-23 signalling (187). The role of STAT3 in Tregs biology is however 
not straightforward. While independent data confirm that the IL-6-STAT3 axis suppresses initial Treg differentiation, which is 
instead driven by TGFbeta alone, several lines of evidence suggest that STAT3 is however required for optimal Tregs activity 
(193). Indeed, Treg-specific STAT3 deletion leads to uncontrolled Th17 expansion and fatal Th17-dependent intestinal 
inflammation, even though Treg numbers were unaltered (194). STAT3 was indeed required for the expression of about 20% of 
the Foxp3 target genes, including Il-10 and Il-35. Failure of STAT3-deficient Tregs to properly respond to IL-10, specifically 
impaired their ability to suppress Th17-mediated inflammation (195). Moreover, STAT3 triggered repression of the IL-6 and 
TGFbeta genes by recruiting Foxp3 to their promoters. These observations are in line with those of Kortylewski and colleagues, 
who showed that STAT3-dependent IL-23 production by tumour infiltrating macrophages enhanced Foxp3 and IL-10 expression 
in Tregs via STAT3 activation (196). 
 
5. IL-6, TH17 AND STAT3: THE HOLY TRINITY IN AUTO-IMMUNITY? 
 
The role of STAT3 in Th17 differentiation implicates its involvement in auto-immune disorders, as also suggested by 
the identification of polymorphisms associated with greater risk of auto-immune disease (197). STAT3 is activated in synovial 
lining cells and in freshly isolated SF from RA patients (198),   and  patient’s  SF   transduced  with a dominant negative form of 
STAT3 undergo apoptosis and growth arrest (199). STAT3 may promote SF survival by opposing the proapoptotic effects 
delivered by EGF and STAT1 and by maintaining myc expression (199).  
 
Several studies in animal models support the idea that the IL-6/IL-17/STAT3 loop is a key factor in regulating auto-
immunity. Two different knock-in mouse strains have been generated mutating the tyrosine residue of gp130 involved in 
recruiting both SOCS3 and SHP2, Y757 in the mouse and Y759 in humans (200, 201). While Ohtani et al. generated a mutant 
allele carrying the human intracytoplasmic portion of gp130, and designated their strain gp130F759/F759 (200), Jenkins et al. 
directly introduced the Y to F point mutation in the mouse sequence, denominating their strain gp130Y757/Y757 (201). Both mutant 
strains lack SOCS3-mediated negative feedback, thus displaying enhanced gp130-mediated STAT3 activation. Lack of SHP2 
recruitment, in addition, leads to impaired activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase 
(ERK/MAPK) pathway. Different phenotypes were described for the two strains. While gp130F759/F759  mice undergo a 
spontaneous lymphocyte-mediated rheumatoid arthritis-like joint disease (202), gp130Y757/Y757 mice develop gastric tumours 
(203). The reasons for this difference are presently unknown and may relate to slight variations in signalling sensitivity (204). 
Arthritis in the gp130F759/F759 mice is characterized by high serum levels of IL-17, IL-6 and sIL-6R and by increased numbers of 
Th17 cells in the spleen and lymph nodes (180, 205). Disease development is dependent on both IL-17 and IL-6, since it is 
strongly reduced in gp130F759/F759 mice where the Il-17A or Il-6 genes were inactivated (172). Moreover, it could be shown that 
IL-6 functions are required also downstream of IL-17, since arthritis in IL-17-/- F759 mice could be rescued by IL-6 expression 
while IL-17 could not trigger disease development in the IL-6-/- F759 mice. Finally, specific deletion of STAT3 in type I collagen 
fibroblasts suppressed arthritis development, arguing for a crucial role of this factor in cells of the local stroma (205), and 
suggesting that hyper-STAT3 activity rather than impaired MAPK activation is responsible for the observed phenotype. IL-17 
and IL-6 appear therefore to participate to a positive feedback loop as depicted in Figure 2, where STAT3 drives naïve T cells to 
differentiate into Th17 lymphocytes, which in turn produce IL-17 thus stimulating stromal cells to express and secrete IL-6. This 
was shown to require the activity of both STAT3 and NF-kB (205). IL-6 production in turn, in combination with TGFbeta, leads 
to increased STAT3-dependent Th17 differentiation and, in association with soluble IL-6R, acts on stromal cells to induce the 
secretion of pro-inflammatory chemokines. As already mentioned, IL-6R expression is cell type-restricted. Stromal cells are 
typically devoid of the membrane-bound IL-6R form, and must therefore rely on trans-signalling for IL-6 responses (59). Finally, 
IL-6-induced chemokines recruit immune cells that, producing IL-23, sustain Th17 cells survival and increase inflammation. 
Dysregulation of this pathway is likely involved in other auto-immune diseases, as it was already shown for EAE (205). 
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Accordingly, in vivo inhibition of the gp130-associated JAK1 and JAK2 can ameliorate CIA in mice and AIA in rats, leading to a 
reduced expression of pathogenic cytokines including IL-6, IL-17 and IL-23 and to reduced Th1/Th17 cell numbers (206). On the 
other hand, IFNb  treatment improved EAE symptoms, down-regulating the Th17 response via decreased STAT3 and 
increased STAT1 phosphorylation in CD4+ T cells (207). This may in part explain the efficacy of IFNbeta therapy in MS patients 
(208). Finally, it was recently reported that p53-null CD45.1 mice develop kidney auto-immunity, characterized by increased 
Th17 cell numbers in the lymph nodes and increased serum IL-17 and IL-6 levels. This correlated with enhanced STAT3 
phosphorylation following IL-6 stimulation of T lymphocytes (209). Interestingly, the STAT3 inhibitor S3I (210) suppressed 
Th17 cells expansion and alleviated the auto-immune disease. 
 
6. THE IL-6-IL-17-STAT3 LOOP IN INFLAMMATION-DRIVEN TUMOURIGENESIS 
 
It is well recognized that the microenvironment of chronic inflammation represents a tumour-predisposing niche, where 
both tumour initiation and promotion of resident cells can be triggered by means of different mechanisms. In particular, 
continuous exposure to reactive oxygen species (ROS) may cause genetic mutations, and cytokines and chemokines can induce 
epigenetic mutations and activate transcription factors such as STAT3 and NF-kB. These are constitutively activated in most 
tumours as a consequence of chronic signalling from upstream receptors and oncogenes (211), and in turn act in a coordinated 
way to enhance survival, proliferation, angiogenesis and invasions, promoting survival of initially transformed cells as well as 
tumour growth and metastasis (212). Moreover, virtually all solid tumours cause chronic inflammation of their microenvironment 
that likely contributes to tumour expansion and growth even for those tumours where no proven cause-relationship exists (213).  
 
In addition to persistent infections with several microbial agents, which are associated with the development of gastric 
cancer, hepatocellular carcinoma, bladder or colon cancer, another leading cause of chronic inflammation is dysregulation of the 
immune responses and auto-immunity. An outstanding example is inflammatory bowel disease (IBD), which is associated with 
highly increased risk of developing colorectal cancer (214). By no means, however, do all chronic inflammatory or auto-immune 
conditions increase cancer risk, although the reasons for this are not yet understood. IL-6, which in association with TNFalpha 
and IL-1beta can sustain chronic inflammation, is one of the major factors involved in these processes mainly through STAT3 
signalling (213). For example, intestinal levels of IL-6 and sIL-6R are elevated in IBD patients, correlating with clinical activity 
(215, 216). Serum IL-6 levels are elevated in many types of human cancers, and the IL-6 signalling cascade represents an 
attractive therapeutic target in cancer (217, 218). Indeed, IL-6 deficiency or specific STAT3 ablation in the colon epithelium 
blocks the induction and growth of colitis-associated cancer (219), and blockage of IL-6 trans-signalling suppresses the 
development of colitis-associated premalignant cancer in both the AOM and DSS models (16, 220) as well as enhancing the 
sensitivity of ovarian tumours to chemotherapy (221).  
 
 Even though the role of IL-17 in cancer is still controversial, a number of recent publications suggest that Th17 cells 
and IL-17 may also enter the picture. The role of Th17 cells may vary according to tumour type, since the presence of Th17 cells 
in human tumours has been associated with both bad and good prognosis (222, 223). Ovarian cancers, which are highly 
inflammatory and where IL-6 production and STAT3 are considered to play a major role (224), have been shown to contain high 
percentages of Th17 cells, and ovary tumour cells produce high amounts of IL-6 and TGFbeta, among other cytokines (222). 
Two reports suggest an anti-tumoural role of Th17 responses, describing increased tumour growth of lung metastasis and higher 
susceptibility to lung melanoma in IL-17A-deficient mice (225, 226). However, xenografts of different kind of tumoural cells 
(melanoma, bladder cancer, lymphoma, prostate cancer) have been shown to grow poorly in IL-17 or IL-17R-deficient mice 
(227, 228), and more efficiently in IFNgamma or IFNgammaR mutant mice. IL-17 produced by intra-tumour CD4+ T 
lymphocytes stimulates IL-6 production by both tumour and stromal cells, thus enhancing constitutive STAT3 activation and 
tumour cells survival, proliferation and angiogenesis (227). Finally, IL-17-deficient mice are strongly protected from 
DMBA/TPA-induced skin cancer (229), correlating with decreased IL-6 production and STAT3 phosphorylation in the tumour 
microenvironment, decreased expression of STAT3-regulated chemokines and consequent reduced infiltration of myeloid cells. 
Of note, this model of skin cancer is known to be completely STAT3-dependent (230). In contrast, in spite of increased 
expression of IL-17-related factors in gp130Y757/Y757 mice, IL-17A ablation in these mice does not alter the onset or development 
of gastric tumours, suggesting independence from Th17 lymphocytes. Accordingly, IL-17A expression is not up-regulated in 
gastric cancer (231).  
 
 Taken together, these data suggest that a feed forward loop between IL-6, IL-17 and STAT3 similar to the 
one described above and depicted in Figure 2 for auto-immunity may well play an important role in at least a subset of 
inflammation-driven tumours.  
 
6. CONCLUSIONS 
 
IL-17, IL-6 and STAT3 appear to be strictly functionally linked, such that aberrant up-regulation of one member leads 
to dysregulated activity of the others in a circular positive feedback loop, and this chronic dysregulation appears to be of 
paramount importance in the development of both auto-immune disorders and cancer. Indeed, IL-6 neutralizing antibodies have 
already been approved for the treatment of rheumatoid arthritis and tested for several other auto-immune disorders (62), and are 
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likewise being tested for the treatment of human cancers (reviewed in (232)). In the light of the above considerations, combined 
therapeutic approaches hitting multiple players in the game may be a desirable strategy for both kinds of diseases. 
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Figure 1. IL-6 signalling and trans-signalling. IL-6 interacts with its ligand-binding receptor, the IL-6Ralpha, either membrane-
bound (classical signaling) or in a soluble form (trans-signaling), and the complex associates with gp130 triggering its 
dimerization and consequent activation of the associated JAK kinases. These mediate the phosphorylation of specific tyrosine 
residues (P) on the gp130 cytoplasmic tail, which in turn act as docking sites for STAT3 (and STAT1) SH2 domains, leading to 
JAK-mediated STAT3 phosphorylation, dimerization and concentration in the nucleus, where it regulates transcription of target 
genes. SOCS3 negatively regulates IL-6 signaling by interacting with gp130 phosphotyrosine-759 and leading to the inhibition of 
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JAK activity through its kinase inhibitory region. Soluble forms of both IL-6Ralpha and gp130 (sIL-6Ralpha, sgp130), which 
lack the transmembrane and cytoplasmic parts, are highly produced under pathological conditions, acting as IL-6 trans-signaling 
agonist (sIL-6Ralpha) or antagonist (sgp130), respectively.  
 
Figure 2. The positive feedback loop between IL-6, IL-17 and STAT3. IL-6 in combination with TGFbeta promotes STAT3-
dependent Th17 differentiation of naïve CD4+ T cells, while TGFbeta in the absence of IL-6 triggers the differentiation of 
TGFbeta T regulatory cells (Tregs). The proinflammatory cytokine IL-23 triggers Th17 expansion, but full responsiveness to IL-
23 requires STAT3-dependent IL-23R up-regulation by IL-6. IL-17, the main cytokine produced by Th17 cells, provides defence 
against extracellular bacteria and mediates inflammation, tissue damage and recruitment of immune cells. IL-17 acts on stromal 
cells to sustain NF-kB-mediated IL-6 expression, which in turn enhances Th17 differentiation in a positive feedback loop. In 
addition, stimulated stromal cells attract neutrophils, which generate sIL-6R by shedding thus leading to trans-signaling in 
combination with IL-6, further amplifying and sustaining inflammation. , membrane-bound IL-6 receptor; , membrane-bound 
IL-23 receptor; red P-ST3 or NF-kB indicate phospho-STAT3 or NF-kB dependent effects. 
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